Mirum Pharmaceuticals, Inc. (MIRM) Misses Q1 EPS by 1309c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street slides as AI cash burn worries spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil prices set for fourth straight monthly gains as tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Join SI Premium – FREE
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q1 EPS of ($13.43), $13.09 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $159.9 million versus the consensus estimate of $148.8 million.
GUIDANCE:
Mirum Pharmaceuticals, Inc. sees FY2026 revenue of $660-680 million, versus the consensus of $643.3 million.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
- John B. Sanfilippo & Son, Inc. (JBSS) PT Lowered to $79 at Freedom Broker
- nVent Electric (NVT) Tops Q3 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
